DOCSLIB.ORG

Mouse Ccnc Conditional Knockout Project (CRISPR/Cas9)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mouse Ccnc Conditional Knockout Project (CRISPR/Cas9) https://www.alphaknockout.com Mouse Ccnc Conditional Knockout Project (CRISPR/Cas9) Objective: To create a Ccnc conditional knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Ccnc gene (NCBI Reference Sequence: NM_001290422 ; Ensembl: ENSMUSG00000028252 ) is located on Mouse chromosome 4. 13 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 12 (Transcript: ENSMUST00000065928). Exon 2~4 will be selected as conditional knockout region (cKO region). Deletion of this region should result in the loss of function of the Mouse Ccnc gene. To engineer the targeting vector, homologous arms and cKO region will be generated by PCR using BAC clone RP24-369K6 as template. Cas9, gRNA and targeting vector will be co-injected into fertilized eggs for cKO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Homozygous null mice die prenatally and exhibit growth retardation and placental defects. Exon 2 starts from about 3.9% of the coding region. The knockout of Exon 2~4 will result in frameshift of the gene. The size of intron 1 for 5'-loxP site insertion: 2481 bp, and the size of intron 4 for 3'-loxP site insertion: 2858 bp. The size of effective cKO region: ~2662 bp. The cKO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 2 3 4 13 Targeting vector Targeted allele Constitutive KO allele (After Cre recombination) Legends Exon of mouse Ccnc Homology arm cKO region loxP site Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot Window size: 10 bp Forward Reverse Complement Sequence 12 Note: The sequence of homologous arms and cKO region is aligned with itself to determine if there are tandem repeats. Tandem repeats are found in the dot plot matrix. It may be difficult to construct this targeting vector. Overview of the GC Content Distribution Window size: 300 bp Sequence 12 Summary: Full Length(9162bp) | A(28.76% 2635) | C(19.05% 1745) | T(30.89% 2830) | G(21.31% 1952) Note: The sequence of homologous arms and cKO region is analyzed to determine the GC content. Significant high GC-content regions are found. It may be difficult to construct this targeting vector. Page 3 of 8 https://www.alphaknockout.com BLAT Search Results (up) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr4 + 21727148 21730147 3000 browser details YourSeq 52 1319 1430 3000 93.4% chr5 - 60300538 60300651 114 browser details YourSeq 50 1359 1438 3000 79.4% chr13 - 61534540 61534612 73 browser details YourSeq 50 1359 1438 3000 77.7% chr12 + 82015625 82015697 73 browser details YourSeq 45 1147 1438 3000 64.8% chr1 + 54954216 54954353 138 browser details YourSeq 44 1383 1438 3000 87.3% chr18 + 33555934 33555984 51 browser details YourSeq 44 2869 2969 3000 95.9% chr12 + 51613587 51614129 543 browser details YourSeq 43 1359 1438 3000 81.3% chrX + 63211625 63211697 73 browser details YourSeq 38 1388 1438 3000 83.4% chr4 + 126389493 126389538 46 browser details YourSeq 38 2907 2999 3000 75.9% chr18 + 46338315 46338405 91 browser details YourSeq 37 1395 1438 3000 93.1% chr11 - 12839044 12839088 45 browser details YourSeq 37 1348 1400 3000 86.3% chr1 + 26447345 26447407 63 browser details YourSeq 35 1380 1438 3000 94.9% chrX + 60170238 60170817 580 browser details YourSeq 35 1835 1878 3000 90.0% chr1 + 7888781 7888823 43 browser details YourSeq 34 1380 1427 3000 94.8% chr5 - 124409151 124409538 388 browser details YourSeq 33 1388 1438 3000 78.4% chr19 - 36922524 36922567 44 browser details YourSeq 32 1388 1427 3000 82.4% chr5 + 140694515 140694549 35 browser details YourSeq 31 2907 2964 3000 87.9% chrX + 152397776 152397831 56 browser details YourSeq 29 1359 1401 3000 87.1% chr11 - 96236544 96236584 41 browser details YourSeq 29 1359 1401 3000 83.8% chr10 + 52144970 52145012 43 Note: The 3000 bp section upstream of Exon 2 is BLAT searched against the genome. No significant similarity is found. BLAT Search Results (down) QUERY SCORE START END QSIZE IDENTITY CHROM STRAND START END SPAN ----------------------------------------------------------------------------------------------- browser details YourSeq 3000 1 3000 3000 100.0% chr4 + 21732810 21735809 3000 browser details YourSeq 87 662 834 3000 80.5% chr10 + 103595519 103595685 167 browser details YourSeq 84 1575 1859 3000 92.0% chr1 + 36058383 36058775 393 browser details YourSeq 81 667 808 3000 78.7% chr12 + 31383906 31384038 133 browser details YourSeq 80 680 808 3000 80.4% chr10 + 70768712 70768833 122 browser details YourSeq 75 685 825 3000 84.0% chr1 + 120751367 120751508 142 browser details YourSeq 72 668 822 3000 82.4% chr15 - 79415555 79415696 142 browser details YourSeq 71 700 834 3000 85.9% chr7 - 144431776 144431922 147 browser details YourSeq 71 669 836 3000 80.0% chr11 + 86393056 86393193 138 browser details YourSeq 67 330 443 3000 81.9% chr5 - 33225534 33225621 88 browser details YourSeq 67 672 808 3000 80.3% chr5 - 30983704 30983833 130 browser details YourSeq 66 167 392 3000 92.5% chrX + 74216579 74216805 227 browser details YourSeq 66 644 762 3000 84.4% chr12 + 30757071 30757625 555 browser details YourSeq 65 667 807 3000 84.0% chr10 - 69333013 69333142 130 browser details YourSeq 64 700 829 3000 75.3% chr9 + 100974665 100974777 113 browser details YourSeq 63 176 393 3000 88.9% chr1 - 11207956 11208177 222 browser details YourSeq 63 669 770 3000 79.3% chr1 + 84570440 84570532 93 browser details YourSeq 62 680 773 3000 79.1% chr1 - 73753982 73754068 87 browser details YourSeq 61 672 808 3000 82.8% chr10 - 59440769 59440902 134 browser details YourSeq 61 342 478 3000 78.9% chr4 + 99927319 99927423 105 Note: The 3000 bp section downstream of Exon 4 is BLAT searched against the genome. No significant similarity is found. Page 4 of 8 https://www.alphaknockout.com Gene and protein information: Ccnc cyclin C [ Mus musculus (house mouse) ] Gene ID: 51813, updated on 14-Aug-2019 Gene summary Official Symbol Ccnc provided by MGI Official Full Name cyclin C provided by MGI Primary source MGI:MGI:1858199 See related Ensembl:ENSMUSG00000028252 Gene type protein coding RefSeq status VALIDATED Organism Mus musculus Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; Murinae; Mus; Mus Also known as CG1C; AI451004; AU020987 Expression Ubiquitous expression in CNS E18 (RPKM 5.3), CNS E14 (RPKM 4.7) and 28 other tissues See more Orthologs human all Genomic context Location: 4; 4 A3 See Ccnc in Genome Data Viewer Exon count: 14 Annotation release Status Assembly Chr Location 108 current GRCm38.p6 (GCF_000001635.26) 4 NC_000070.6 (21727701..21759922) Build 37.2 previous assembly MGSCv37 (GCF_000001635.18) 4 NC_000070.5 (21654850..21677693) Chromosome 4 - NC_000070.6 Page 5 of 8 https://www.alphaknockout.com Transcript information: This gene has 8 transcripts Gene: Ccnc ENSMUSG00000028252 Description cyclin C [Source:MGI Symbol;Acc:MGI:1858199] Location Chromosome 4: 21,727,701-21,759,922 forward strand. GRCm38:CM000997.2 About this gene This gene has 8 transcripts (splice variants), 206 orthologues, is a member of 1 Ensembl protein family and is associated with 4 phenotypes. Transcripts Name Transcript ID bp Protein Translation ID Biotype CCDS UniProt Flags Ccnc-201 ENSMUST00000065928.10 3484 282aa ENSMUSP00000069076.4 Protein coding CCDS51127 Q8CAS3 TSL:1 GENCODE basic APPRIS ALT1 Ccnc-202 ENSMUST00000102997.7 3365 283aa ENSMUSP00000100062.1 Protein coding CCDS17998 Q62447 TSL:1 GENCODE basic APPRIS P3 Ccnc-204 ENSMUST00000120679.7 1453 266aa ENSMUSP00000113682.1 Protein coding CCDS71350 Q3UXL9 TSL:1 GENCODE basic Ccnc-203 ENSMUST00000108240.2 1406 282aa ENSMUSP00000103875.2 Protein coding CCDS51127 Q8CAS3 TSL:1 GENCODE basic APPRIS ALT1 Ccnc-205 ENSMUST00000123294.7 1404 No protein - lncRNA - - TSL:1 Ccnc-207 ENSMUST00000133712.1 1247 No protein - lncRNA - - TSL:1 Ccnc-206 ENSMUST00000133597.7 1211 No protein - lncRNA - - TSL:1 Ccnc-208 ENSMUST00000145288.7 445 No protein - lncRNA - - TSL:1 Page 6 of 8 https://www.alphaknockout.com 52.22 kb Forward strand 21.72Mb 21.73Mb 21.74Mb 21.75Mb 21.76Mb Genes (Comprehensive set... Ccnc-201 >protein coding Usp45-208 >lncRNA Ccnc-204 >protein coding Ccnc-202 >protein coding Ccnc-206 >lncRNA Ccnc-205 >lncRNA Ccnc-203 >protein coding Ccnc-208 >lncRNA Ccnc-207 >lncRNA Contigs AL772187.6 > Genes < Tstd3-201protein coding (Comprehensive set... Regulatory Build 21.72Mb 21.73Mb 21.74Mb 21.75Mb 21.76Mb Reverse strand 52.22 kb Regulation Legend CTCF Enhancer Open Chromatin Promoter Promoter Flank Gene Legend Protein Coding merged Ensembl/Havana Ensembl protein coding Non-Protein Coding RNA gene Page 7 of 8 https://www.alphaknockout.com Transcript: ENSMUST00000065928 22.85 kb Forward strand Ccnc-201 >protein coding ENSMUSP00000069... MobiDB lite Superfamily Cyclin-like superfamily SMART Cyclin-like Pfam Cyclin, N-terminal Cyclin, C-terminal domain 2 PIRSF PIRSF028758 PANTHER PTHR10026 Cyclin C/cyclin-like subunit Ssn8 Gene3D 1.10.472.10 CDD Cyclin-like All sequence SNPs/i... Sequence variants (dbSNP and all other sources) Variant Legend missense variant synonymous variant Scale bar 0 40 80 120 160 200 240 282 We wish to acknowledge the following valuable scientific information resources: Ensembl, MGI, NCBI, UCSC. Page 8 of 8.
Load more

Recommended publications
  • Anti-Cdk8 Antibody Produced in Rabbit (C0238)
    ANTI-CDK8 Developed in Rabbit, Affinity Isolated Antibody Product Number C 0238 Product Description Reagent Anti-Cyclin-Dependent Kinase 8 (CDK8) is developed in Anti-CDK8, at approximately 1 mg/ml, is supplied as a rabbit using a synthetic peptide corresponding to the solution in phosphate buffered saline, pH 7.4 containing C-terminal region (aa 451-464) of human CDK8. The 0.2% BSA and 15 mM sodium azide. antibody is purified by protein A affinity chromatography. Anti-CDK8 specifically recognizes a 54 kDa protein Precautions and Disclaimer identified as cyclin-dependent kinase 8 (CDK8). Anti- Due to the sodium azide content, a material safety data CDK8 does not crossreact with the other members of sheet (MSDS) for this product has been sent to the CDK family. It detects human, mouse and rat CDK8. It attention of the safety officer of your institution. Consult is used in immunoblotting, immunoprecipitation and the MSDS for information regarding hazardous and safe immunofluorescence applications. handling practices. Cyclin-dependent kinase 8 (CDK8) is a 464-amino acid Storage/Stability protein containing the sequence motifs and 11 Store at –20 °C. For extended storage, upon initial subdomains characteristic of a serine/threonine-specific thawing, freeze the solution in working aliquots. kinase.1 CDKs become activated through binding to Avoid repeated freezing and thawing to prevent cyclins, formation of cyclin-CDK complexes and denaturing the antibody. Storage in “frost-free” reversible phosphorylation reactions. Cyclin-CDK freezers is also not recommended. If slight complexes directly control progression through G1, S, turbidity occurs upon prolonged storage, clarify the G2 and M phases of the cell division cycle.
    [Show full text]
  • Regulatory Functions of the Mediator Kinases CDK8 and CDK19 Charli B
    TRANSCRIPTION 2019, VOL. 10, NO. 2, 76–90 https://doi.org/10.1080/21541264.2018.1556915 REVIEW Regulatory functions of the Mediator kinases CDK8 and CDK19 Charli B. Fant and Dylan J. Taatjes Department of Biochemistry, University of Colorado, Boulder, CO, USA ABSTRACT ARTICLE HISTORY The Mediator-associated kinases CDK8 and CDK19 function in the context of three additional Received 19 September 2018 proteins: CCNC and MED12, which activate CDK8/CDK19 kinase function, and MED13, which Revised 13 November 2018 enables their association with the Mediator complex. The Mediator kinases affect RNA polymerase Accepted 20 November 2018 II (pol II) transcription indirectly, through phosphorylation of transcription factors and by control- KEYWORDS ling Mediator structure and function. In this review, we discuss cellular roles of the Mediator Mediator kinase; enhancer; kinases and mechanisms that enable their biological functions. We focus on sequence-specific, transcription; RNA DNA-binding transcription factors and other Mediator kinase substrates, and how CDK8 or CDK19 polymerase II; chromatin may enable metabolic and transcriptional reprogramming through enhancers and chromatin looping. We also summarize Mediator kinase inhibitors and their therapeutic potential. Throughout, we note conserved and divergent functions between yeast and mammalian CDK8, and highlight many aspects of kinase module function that remain enigmatic, ranging from potential roles in pol II promoter-proximal pausing to liquid-liquid phase separation. Introduction and MED13L associate in a mutually exclusive fash- ion with MED12 and MED13 [12], and their poten- The CDK8 kinase exists in a 600 kDa complex tial functional distinctions remain unclear. known as the CDK8 module, which consists of four CDK8 is considered both an oncogene [13–15] proteins (CDK8, CCNC, MED12, MED13).
    [Show full text]
  • Structure and Mechanism of the RNA Polymerase II Transcription Machinery
    Downloaded from genesdev.cshlp.org on October 9, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Structure and mechanism of the RNA polymerase II transcription machinery Allison C. Schier and Dylan J. Taatjes Department of Biochemistry, University of Colorado, Boulder, Colorado 80303, USA RNA polymerase II (Pol II) transcribes all protein-coding ingly high resolution, which has rapidly advanced under- genes and many noncoding RNAs in eukaryotic genomes. standing of the molecular basis of Pol II transcription. Although Pol II is a complex, 12-subunit enzyme, it lacks Structural biology continues to transform our under- the ability to initiate transcription and cannot consistent- standing of complex biological processes because it allows ly transcribe through long DNA sequences. To execute visualization of proteins and protein complexes at or near these essential functions, an array of proteins and protein atomic-level resolution. Combined with mutagenesis and complexes interact with Pol II to regulate its activity. In functional assays, structural data can at once establish this review, we detail the structure and mechanism of how enzymes function, justify genetic links to human dis- over a dozen factors that govern Pol II initiation (e.g., ease, and drive drug discovery. In the past few decades, TFIID, TFIIH, and Mediator), pausing, and elongation workhorse techniques such as NMR and X-ray crystallog- (e.g., DSIF, NELF, PAF, and P-TEFb). The structural basis raphy have been complemented by cryoEM, cross-linking for Pol II transcription regulation has advanced rapidly mass spectrometry (CXMS), and other methods. Recent in the past decade, largely due to technological innova- improvements in data collection and imaging technolo- tions in cryoelectron microscopy.
    [Show full text]
  • Highly Frequent Allelic Loss of Chromosome 6Q16-23 in Osteosarcoma: Involvement of Cyclin C in Osteosarcoma
    1153-1158 5/11/06 16:31 Page 1153 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 18: 1153-1158, 2006 Highly frequent allelic loss of chromosome 6q16-23 in osteosarcoma: Involvement of cyclin C in osteosarcoma NORIHIDE OHATA1, SACHIO ITO2, AKI YOSHIDA1, TOSHIYUKI KUNISADA1, KUNIHIKO NUMOTO1, YOSHIMI JITSUMORI2, HIROTAKA KANZAKI2, TOSHIFUMI OZAKI1, KENJI SHIMIZU2 and MAMORU OUCHIDA2 1Science of Functional Recovery and Reconstruction, 2Department of Molecular Genetics, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1, Okayama 700-8558, Japan Received June 13, 2006; Accepted August 14, 2006 Abstract. The molecular pathogenesis of osteosarcoma is very rearrangements (1,2). It has been reported that both RB1 and complicated and associated with chaotic abnormalities on many TP53 pathways are inactivated, and the regulation of cell cycle chromosomal arms. We analyzed 12 cases of osteosarcomas is impaired in most osteosarcomas (1). For example, deletion/ with comparative genomic hybridization (CGH) to identify mutation of the CDKN2A gene encoding both p16INK4A and chromosomal imbalances, and detected highly frequent p14ARF on 9p21 (3-5), amplification of the CDK4 (6), CCND1, chromosomal alterations in chromosome 6q, 8p, 10p and MDM2 genes (4), and other aberrations related to inactivation 10q. To define the narrow rearranged region on chromosome 6 of these pathways have been found. Tumor suppressor genes with higher resolution, loss of heterozygosity (LOH) analysis (TSGs) are suspected to be involved in tumorigenesis of was performed with 21 microsatellite markers. Out of 31 cases, osteosarcoma. Loss of heterozygosity (LOH) studies have 23 cases (74%) showed allelic loss at least with one marker on detected frequent allelic loss at 3q, 13q, 17p and 18q (7).
    [Show full text]
  • The Pennsylvania State University the Graduate School Department
    The Pennsylvania State University The Graduate School Department of Pharmacology ALTERATIONS IN GENE EXPRESSION AS A RESPONSE OF TUMOR CELLS TO STRESSES A Dissertation in Pharmacology by Kathryn Joyce Huber-Keener 2012 Kathryn Joyce Huber-Keener Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy May 2013 The dissertation of Kathryn Joyce Huber-Keener was reviewed and approved* by the following: Jin-Ming Yang Professor of Pharmacology Dissertation Advisor Chair of Committee Willard M. Freeman Associate Professor of Pharmacology Rongling Wu Professor of Statistics Robert G. Levenson Professor of Pharmacology Andrea Manni Professor of Medicine Jong K. Yun Director of the Pharmacology Graduate Program *Signatures are on file in the Graduate School ii ABSTRACT Solid cancers are the 2nd leading cause of death in adults in the United States. Understanding the mechanisms by which cancer cells survive under stress is pivotal to decreasing this statistic. Cancer cells are constantly under stress, a factor which needs to be taken into consideration during the treatment of solid cancers. Both intrinsic and extrinsic stresses impact the development and progression of neoplasms, down to the level of individual proteins and genes. Stresses like nutrient deficiency, hypoxia, acidity, and the immune response are present during normal tumor growth and throughout treatment. Tumor cells that survive these stresses are more adept at surviving hostile conditions and are more resistant to current therapies. Stress, therefore, shapes the tumor cell population. Gene expression alterations are the driving feature behind the adaptive ability of cancer cells to these stresses, and therefore, careful examination of these gene expression changes must be undertaken in order to develop effective therapies for solid cancers.
    [Show full text]
  • Variation in Protein Coding Genes Identifies Information Flow
    bioRxiv preprint doi: https://doi.org/10.1101/679456; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Animal complexity and information flow 1 1 2 3 4 5 Variation in protein coding genes identifies information flow as a contributor to 6 animal complexity 7 8 Jack Dean, Daniela Lopes Cardoso and Colin Sharpe* 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Institute of Biological and Biomedical Sciences 25 School of Biological Science 26 University of Portsmouth, 27 Portsmouth, UK 28 PO16 7YH 29 30 * Author for correspondence 31 [email protected] 32 33 Orcid numbers: 34 DLC: 0000-0003-2683-1745 35 CS: 0000-0002-5022-0840 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Abstract bioRxiv preprint doi: https://doi.org/10.1101/679456; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Animal complexity and information flow 2 1 Across the metazoans there is a trend towards greater organismal complexity. How 2 complexity is generated, however, is uncertain. Since C.elegans and humans have 3 approximately the same number of genes, the explanation will depend on how genes are 4 used, rather than their absolute number.
    [Show full text]
  • Dissecting the Genetics of Human Communication
    DISSECTING THE GENETICS OF HUMAN COMMUNICATION: INSIGHTS INTO SPEECH, LANGUAGE, AND READING by HEATHER ASHLEY VOSS-HOYNES Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Epidemiology and Biostatistics CASE WESTERN RESERVE UNIVERSITY January 2017 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We herby approve the dissertation of Heather Ashely Voss-Hoynes Candidate for the degree of Doctor of Philosophy*. Committee Chair Sudha K. Iyengar Committee Member William Bush Committee Member Barbara Lewis Committee Member Catherine Stein Date of Defense July 13, 2016 *We also certify that written approval has been obtained for any proprietary material contained therein Table of Contents List of Tables 3 List of Figures 5 Acknowledgements 7 List of Abbreviations 9 Abstract 10 CHAPTER 1: Introduction and Specific Aims 12 CHAPTER 2: Review of speech sound disorders: epidemiology, quantitative components, and genetics 15 1. Basic Epidemiology 15 2. Endophenotypes of Speech Sound Disorders 17 3. Evidence for Genetic Basis Of Speech Sound Disorders 22 4. Genetic Studies of Speech Sound Disorders 23 5. Limitations of Previous Studies 32 CHAPTER 3: Methods 33 1. Phenotype Data 33 2. Tests For Quantitative Traits 36 4. Analytical Methods 42 CHAPTER 4: Aim I- Genome Wide Association Study 49 1. Introduction 49 2. Methods 49 3. Sample 50 5. Statistical Procedures 53 6. Results 53 8. Discussion 71 CHAPTER 5: Accounting for comorbid conditions 84 1. Introduction 84 2. Methods 86 3. Results 87 4. Discussion 105 CHAPTER 6: Hypothesis driven pathway analysis 111 1. Introduction 111 2. Methods 112 3. Results 116 4.
    [Show full text]
  • Cyclin-Dependent Kinase 8 Mediates Chemotherapy- Induced Tumor-Promoting Paracrine Activities
    Cyclin-dependent kinase 8 mediates chemotherapy- induced tumor-promoting paracrine activities Donald C. Portera,1, Elena Farmakib,1, Serena Altiliaa,c, Gary P. Schoolsc,d, Deborah K. Westa, Mengqian Chend, Bey-Dih Changa, Anatoliy T. Puzyreva, Chang-uk Limc,d, Rebecca Rokow-Kittella, Lawrence T. Friedhoffa, Athanasios G. Papavassilioub, Swathi Kalurupallec, Gregory Hurteauc, Jun Shie, Phil S. Barane, Balazs Gyorffyf, Mark P. Wentlandg, Eugenia V. Broudec,d, Hippokratis Kiarisb, and Igor B. Roninsonc,d,2 aSenex Biotechnology, Inc., Columbia, SC 29208; dDepartment of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC 29208; bLaboratory of Biological Chemistry, University of Athens Medical School, 115 27 Athens, Greece; cCancer Center, Ordway Research Institute, Albany, NY 12208; eDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037; fResearch Laboratory for Pediatrics and Nephrology, Hungarian Academy of Sciences, Budapest H-1083, Hungary; and gDepartment of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, NY 12180 Edited by George R. Stark, Lerner Research Institute, Cleveland, OH, and approved July 16, 2012 (received for review May 8, 2012) Conventional chemotherapy not only kills tumor cells but also changes proteins implicated in age-related diseases (10), and it stimulates gene expression in treatment-damaged tissues, inducing production viral promoters, including those of HIV and CMV (16, 17). p21 of multiple tumor-supporting secreted factors. This secretory pheno- binds several members of the cyclin-dependent kinase (CDK) type was found here to be mediated in part by a damage-inducible family. The best-known CDKs (CDK1, CDK2, CDK4/6) mediate cell-cycle inhibitor p21 (CDKN1A).
    [Show full text]
  • Cyclin C (CCNC) Antibody (C-Term) Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap7835b
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 Cyclin C (CCNC) Antibody (C-term) Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP7835b Specification Cyclin C (CCNC) Antibody (C-term) - Product Information Application WB,E Primary Accession P24863 Other Accession Q4KLA0, P39947, Q62447, P55168, Q3ZCK5 Reactivity Human Predicted Bovine, Chicken, Mouse, Rat, Xenopus Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Calculated MW 33243 Western blot analysis of anti-CCNC Antibody Antigen Region 221-249 (C-term) (Cat.#AP7835b) in HL60 cell line lysates (35ug/lane). CCNC(arrow) was Cyclin C (CCNC) Antibody (C-term) - Additional detected using the purified Pab. Information Gene ID 892 Cyclin C (CCNC) Antibody (C-term) - Background Other Names Cyclin-C, SRB11 homolog, hSRB11, CCNC CCNC is a member of the cyclin family of proteins. This protein interacts with Target/Specificity cyclin-dependent kinase 8 and induces the This Cyclin C (CCNC) antibody is generated phophorylation of the carboxy-terminal domain from rabbits immunized with a KLH of the large subunit of RNA polymerase II. conjugated synthetic peptide between 221-249 amino acids from the C-terminal Cyclin C (CCNC) Antibody (C-term) - region of human Cyclin C (CCNC). References Dilution Katona,R.L., Acta. Biol. Hung. 58 (1), 133-137 WB~~1:1000 (2007) Ohata,N., Int. J. Mol. Med. 18 (6), 1153-1158 Format (2006) Purified polyclonal antibody supplied in PBS Sinkkonen,L., Nucleic Acids Res. 33 (8), with 0.09% (W/V) sodium azide. This 2440-2451 (2005) antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    [Show full text]
  • The Role of Cyclin-Dependent Kinase 8 in Vascular Disease Desiree Leach University of South Carolina
    University of South Carolina Scholar Commons Theses and Dissertations Fall 2017 The Role Of Cyclin-Dependent Kinase 8 In Vascular Disease Desiree Leach University of South Carolina Follow this and additional works at: https://scholarcommons.sc.edu/etd Part of the Biomedical and Dental Materials Commons Recommended Citation Leach, D.(2017). The Role Of Cyclin-Dependent Kinase 8 In Vascular Disease. (Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/4523 This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. THE ROLE OF CYCLIN -DEPENDENT KINASE 8 IN VASCULAR DISEASE by Desiree Leach Bachelor of Science Coastal Carolina University, 2010 Submitted in Partial Fulfillment of the Requirements For the Degree of Doctor of Philosophy in Biomedical Science School of Medicine University of South Carolina 2017 Accepted by: Taixing Cui, Major Professor Wayne Carver, Committee Member Joseph Janicki, Committee Member Igor Roninson, Committee Member Udai Singh, Committee Member Cheryl L Addy, Vice Provost and Dean of the Graduate School © Copyright by Desiree Leach, 2017 All Rights Reserved. ii ACKNOWLEDGEMENTS I would like to thank my mentor, Dr. Taixing Cui, for all his guidance and support. Thank you for supplying me with the knowledge and techniques to grow as a scientist. I would also like to thank my committee members: Dr. Wayne Carver, Dr. Igor Roninson, Dr. Udai Singh and Dr. Joseph Janicki. I appreciate all of your constructive criticism and your efforts to help me grow as a scientist.
    [Show full text]
  • LETTER Doi:10.1038/Nature14904
    LETTER doi:10.1038/nature14904 Mediator kinase inhibition further activates super-enhancer-associated genes in AML Henry E. Pelish1*, Brian B. Liau1*, Ioana I. Nitulescu1, Anupong Tangpeerachaikul1, Zachary C. Poss2, Diogo H. Da Silva1, Brittany T. Caruso1, Alexander Arefolov1, Olugbeminiyi Fadeyi1, Amanda L. Christie3, Karrie Du1, Deepti Banka4, Elisabeth V. Schneider5,6, Anja Jestel5,GeZou1, Chong Si1, Christopher C. Ebmeier2, Roderick T. Bronson7, Andrei V. Krivtsov8, Andrew G. Myers1, Nancy E. Kohl3, Andrew L. Kung9, Scott A. Armstrong8, Madeleine E. Lemieux10, Dylan J. Taatjes2 & Matthew D. Shair1 Super-enhancers (SEs), which are composed of large clusters of terms pertinent to haematopoiesis, cellular differentiation and tran- enhancers densely loaded with the Mediator complex, transcrip- scription, supporting the notion that SEs regulate cellular identity tion factors and chromatin regulators, drive high expression of (Supplementary Table 1). genes implicated in cell identity and disease, such as lineage- To determine whether pharmacological inhibition of Mediator controlling transcription factors and oncogenes1,2. BRD4 and kinases regulates SE function and inhibits AML proliferation, in ana- CDK7 are positive regulators of SE-mediated transcription3–5.By logy to BRD4, we characterized CA (Fig. 2a) as an inhibitor of CDK8 contrast, negative regulators of SE-associated genes have not been and its paralogue CDK19 (77% identical overall and 94% in the cata- well described. Here we show that the Mediator-associated kinases lytic domain). CA was reported to bind CDK8 and CDK19, as well as cyclin-dependent kinase 8 (CDK8) and CDK19 restrain increased ROCK1 and ROCK2, as individual proteins in vitro10. We synthesized activation of key SE-associated genes in acute myeloid leukaemia CA11,12 and determined that it potently inhibited the kinase activity of (AML) cells.
    [Show full text]
  • Therapeutic Resistance: Blocking the Gatekeeper
    RESEARCH HIGHLIGHTS IN BRIEF IMMUNOTHERAPY A lethal storm The use of cancer immunotherapies can result in severe toxic effects. As cancer is primarily a disease of ageing, Mirsoian et al. have examined the toxicity of immunotherapy in aged mice. The authors previously showed that treatment of young mice with an immune-stimulatory therapy including interleukin-2 (IL-2) and a monoclonal antibody against CD40 (anti-CD40) reduced tumour growth and was well tolerated. However, in aged mice this treatment induced a cytokine storm that was 100% lethal. They have now found that levels of visceral fat in mice increase with age. Young obese mice have similar levels of visceral fat to aged mice, and IL-2 and anti-CD40 treatment also induces a lethal cytokine storm in these mice, whereas calorie-restricted aged mice have less visceral fat and are protected from treatment toxicity. ORIGINAL RESEARCH PAPER Mirsoian, A. et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med. http://dx.doi.org/10.1084/jem.20140116 (2014) LEUKAEMIA Explaining gender bias T cell acute lymphoblastic leukaemia (T-ALL) develops more frequently in males than females. Van der Meulen et al. found that the X chromosome gene UTX, which encodes a demethylase of histone H3 lysine 27 trimethylation contains loss-of-function somatic mutations exclusively in males with T-ALL but escapes X chromosome-inactivation in females. They further showed that UTX acts as a tumour suppressor in vitro and in vivo, and that T-ALL with UTX loss is sensitive to a histone methyltransferase inhibitor.
    [Show full text]